Breaking News, Collaborations & Alliances

Eisai, FORMA in Discovery Pact

DOS platforms to support Eisai portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai Inc. has signed a strategic drug discovery collaboration agreement with FORMA Therapeutics. Eisai will have non-exclusive access to FORMA’s Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai’s pipeline. In addition, Eisai has an option for technology transfer of FORMA’s cell-based screening platform. FORMA will receive upfront payments and committed funding of $20 million over thre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters